ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Illumina Rejects Roche’s Offer

by Ann M. Thayer
February 13, 2012 | APPEARED IN VOLUME 90, ISSUE 7

Illumina’s board has rejected Roche’s $5.7 billion takeover bid. Claiming that the offer undervalues the company’s gene-sequencing business and growth prospects, the board recommends that shareholders not offer their shares to Roche. As the growth of the genetic analysis industry accelerates, “Illumina is singularly positioned to expand its market leadership and to deliver value to our stockholders that is far superior to Roche’s offer,” Illumina CEO Jay T. Flatley says. Roche says it is disappointed in the recommendation and Illumina’s refusal to negotiate a merger. Roche is advancing plans to name its own candidates for election to Illumina’s board.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment